Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-2-16
pubmed:abstractText
Intravenous transplantation of human mesenchymal stem cells (hMSCs) expanded from adult bone marrow ameliorates functional deficits in rat cerebral infarction models. Several hypotheses to account for the therapeutic mechanisms have been suggested, but angiogenesis is thought to be of critical importance. Recently, we have reported the therapeutic benefits of hMSCs which have been transfected with the angiopoietin-1 gene in a rat permanent middle cerebral artery occlusion (MCAO) model. To potentially enhance the therapeutic effects of angiopoietin-1 gene-modified hMSC (Ang-hMSC), we transfected hMSCs with the angiopoietin-1 gene and the VEGF gene, and investigated whether the combination of Ang-1 and VEGF gene-modified hMSCs (Ang-VEGF-hMSC) contribute to functional recovery in a rat MCAO model. We induced MCAO using intraluminal vascular occlusion, and hMSCs, Ang-hMSCs, VEGF-hMSCs or Ang-VEGF-hMSCs were intravenously infused 6 h later. MRI and behavioral analyses revealed that rats receiving Ang-VEGF-hMSCs showed the greatest structural-functional recovery as compared to the other groups. These results suggest that intravenous administration of hMSCs transfected with the angiopoietin-1 and VEGF gene using a fiber-mutant adenovirus vector may represent a new strategy for the treatment of ischemia.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1090-2430
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
216
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
47-55
pubmed:meshHeading
pubmed-meshheading:19094989-Angiopoietin-1, pubmed-meshheading:19094989-Animals, pubmed-meshheading:19094989-Brain, pubmed-meshheading:19094989-Cells, Cultured, pubmed-meshheading:19094989-Cerebral Arteries, pubmed-meshheading:19094989-Disease Models, Animal, pubmed-meshheading:19094989-Gene Therapy, pubmed-meshheading:19094989-Genetic Vectors, pubmed-meshheading:19094989-Humans, pubmed-meshheading:19094989-Hypoxia-Ischemia, Brain, pubmed-meshheading:19094989-Infarction, Middle Cerebral Artery, pubmed-meshheading:19094989-Male, pubmed-meshheading:19094989-Mesenchymal Stem Cell Transplantation, pubmed-meshheading:19094989-Neovascularization, Physiologic, pubmed-meshheading:19094989-Rats, pubmed-meshheading:19094989-Rats, Sprague-Dawley, pubmed-meshheading:19094989-Recovery of Function, pubmed-meshheading:19094989-Treatment Outcome, pubmed-meshheading:19094989-Vascular Endothelial Growth Factor A
pubmed:year
2009
pubmed:articleTitle
Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia.
pubmed:affiliation
Department of Neurosurgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural